康芝藥業(300086.SZ):目前主要在銷售的兒童藥有小兒退熱貼、小兒清解顆粒等
格隆匯3月8日丨康芝藥業(300086.SZ)近日在接待機構投資者調研時表示,公司目前主要在銷售的兒童藥有鹽酸左西替利嗪顆粒(獨家劑型)、布洛芬顆粒、小兒退熱貼、小兒清解顆粒、氨金黃敏顆粒、小兒氨酚黃那敏顆粒、銀胡感冒散、蒙脱石散、鞣酸蛋白酵母散、乳酸菌素顆粒、腸胃散、稚兒靈顆粒、健兒樂顆粒、蒙脱石散、止咳橘紅顆粒、羧甲司坦顆粒、小兒麻甘顆粒、小兒咽扁顆粒、小兒化痰止咳顆粒、頭孢克洛顆粒、利巴韋林顆粒、抗病毒口服液、複方鋅鐵鈣顆粒、羧甲澱粉鈉溶液、硫酸鋅口服液、丙戊酸鈉糖漿等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.